Treatment of Primary Ovarian Lymphoma in Peripheral T-Cell Lymphoma NOS and Follicular Helper T-Cell Lymphoma
Primary ovarian lymphoma presenting as peripheral T-cell lymphoma not otherwise specified (PTCL NOS) or follicular helper T-cell lymphoma (TFHL) represents a distinct clinical scenario that requires a specific first-line management approach tailored to disease stage and risk profile.
Clinical Scenario
This protocol applies to patients with primary ovarian lymphoma whose histological diagnosis is peripheral T-cell lymphoma not otherwise specified (PTCL NOS) or follicular helper T-cell lymphoma (TFHL). The recommended pathway for initial treatment differs based on disease stage and pre-therapeutic risk profile.
First-Line Treatment Approach
First-line induction involves a CHOP or CHOP-like chemotherapy regimen, with or without etoposide, as the backbone of treatment. The specific course and any subsequent consolidation strategy depends on disease stage and response.
The full regimen — including cycle counts, consolidation options, and criteria for escalation — is specified in the structured protocol.
References
DOI: 10.1016/j.annonc.2025.07.014
- First-line treatment of PTCL not otherwise specified (NOS) or follicular helper T-cell lymphoma (TFHL):
- CHOP or CHOP-like ChT with or without etoposide can be offered as first-line induction therapy [II, B].
- For patients with stage I-II, non-bulky PTCL NOS or TFHL and a favourable pre-therapeutic risk profile, an abbreviated course of ChT [e.g. three to four cycles of CHO(E)P] can be considered, followed by consolidative ISRT (e.g. 30-40 Gy) [IV, B].
- For patients with stage III-IV disease, six cycles of CHO(E)P can be recommended [II, B], followed by consideration of consolidative ASCT in responding patients [III, C].
View source ↗